“…It is well established that the CTP domain contains determinants for prolonged survival in the serum (Fares et al, 2010(Fares et al, , 1992Grossmann et al, 1997;Joshi et al, 1995;Lee et al, 2006;Pierce and Parsons, 1981), and it is likely that its absence in the FSHba design contributed to the reduced in vivo activity of this analog. In a recent study we observed that the CTP-like stretch-boCTP, which is not efficiently O-glycosylated, can improve for some extent the pharmacokinetics of a chimeric hCGb subunit (CGbboCTP) compared to a truncated subunit variant that lacked the CTP (Gabay et al, 2014). However, the clearance from the plasma of CGbboCTP was much faster (about 2 folds) compared to the CGb subunit (Gabay et al, 2014).…”